Skip to main content

Sabra Health Care REIT, Inc.

For the period ended Sep 30, 2026. Filed Nov 2, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 2, 2026

SBRA$21.32-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Cash Flows

(in thousands)

Nine Months Ended September 30,
20262025
Cash flows from operating activities:
Net income$44,122$128,363
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization174,289135,591
Non-cash rental and related revenues(1,005)820
Non-cash interest expense7,1105,608
Stock-based compensation expense11,1098,290
Loss on extinguishment of debt—1,154
Provision for (recovery of) loan losses and other reserves104,600(640)
Net gain on sales of real estate(29,652)(5,544)
Impairment of real estate4406,674
Income from unconsolidated joint ventures(6,366)(2,276)
Distributions of earnings from unconsolidated joint ventures5,8145,917
Other non-cash items—(17,183)
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net(16,449)(9,129)
Accounts payable and accrued liabilities19,1403,541
Net cash provided by operating activities313,152261,186
Cash flows from investing activities:
Acquisition of real estate and lease intangibles(516,346)(301,563)
Origination and fundings of loans receivable(994)(5,710)
Origination and fundings of preferred equity investments(2,612)(9)
Additions to real estate(41,058)(24,183)
Escrow deposits for potential investments(60)(500)
Repayments of loans receivable210,74315,442
Repayments of preferred equity investments2,8971,977
Investment in unconsolidated joint ventures—(1,241)
Net proceeds from the sales of real estate156,86043,087
Proceeds from net investment hedges—4,462
Insurance proceeds1361,267
Distributions in excess of earnings from unconsolidated joint ventures—5,557
Net cash used in investing activities(190,434)(261,414)
Cash flows from financing activities:
Net (repayments of) borrowings from revolving credit facility(90,200)174,805
Principal payments on senior unsecured notes—(500,000)
Proceeds from term loans—500,000
Principal payments on secured debt(1,604)(1,562)
Payments of deferred financing costs(111)(4,405)
Payments related to extinguishment of debt—(2,884)
Contributions from noncontrolling interests22,040
Distributions to noncontrolling interests(162)—
Payment of contingent consideration(1,178)—
Issuance of common stock, net163,691188,350
Dividends paid on common stock(227,953)(214,692)
Net cash (used in) provided by financing activities(157,515)141,652
Net (decrease) increase in cash, cash equivalents and restricted cash(34,797)141,424
Effect of foreign currency translation on cash, cash equivalents and restricted cash(261)(245)
Cash, cash equivalents and restricted cash, beginning of period78,14066,339
Cash, cash equivalents and restricted cash, end of period$43,082$207,518
Supplemental disclosure of cash flow information:
Interest paid$69,552$72,820
Supplemental disclosure of non-cash investing activities:
Decrease in loans receivable and other investments due to acquisition of real estate$16,600$—
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.